Total Payments
$309.96
2023 Payments
$31.94
Companies
8
Transactions
17
Medicare Patients
929
Medicare Billing
$561,010
Payment Breakdown by Category
Food & Beverage$309.96 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $309.96 | 17 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $77.79 | 4 | $0 (2022) |
| ABBVIE INC. | $70.72 | 4 | $0 (2022) |
| Amgen Inc. | $50.25 | 3 | $0 (2023) |
| UCB, Inc. | $31.89 | 2 | $0 (2022) |
| AMAG Pharmaceuticals, Inc. | $23.92 | 1 | $0 (2021) |
| Mallinckrodt Hospital Products Inc. | $22.85 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $18.33 | 1 | $0 (2021) |
| Kiniksa Pharmaceuticals, Ltd. | $14.21 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $31.94 | 2 | Amgen Inc. ($17.73) |
| 2022 | $157.28 | 9 | ABBVIE INC. ($70.72) |
| 2021 | $120.74 | 6 | Janssen Biotech, Inc. ($40.34) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/07/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Bone Health | ||||||
| 02/02/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $14.21 | General |
| Category: Not Applicable | ||||||
| 12/21/2022 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: Bone Health | ||||||
| 11/17/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Immunology | ||||||
| 11/03/2022 | ABBVIE INC. | RINVOQ (Biological), HUMIRA | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: IMMUNOLOGY | ||||||
| 10/05/2022 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Bone Health | ||||||
| 09/22/2022 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Immunology | ||||||
| 09/01/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: IMMUNOLOGY | ||||||
| 08/09/2022 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: Immunology | ||||||
| 07/19/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: IMMUNOLOGY | ||||||
| 03/10/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2021 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: Immunology | ||||||
| 09/01/2021 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI ARIA | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Immunology | ||||||
| 08/05/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Immunology | ||||||
| 05/29/2021 | AMAG Pharmaceuticals, Inc. | FERAHEME (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: For the treatment of iron deficiency anemia associated with chronic kidney disease | ||||||
| 05/27/2021 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $18.33 | General |
| Category: Immunology | ||||||
| 04/29/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 405 | 38,373 | $1.7M | $333,498 |
| 2022 | 7 | 238 | 12,524 | $1.3M | $157,288 |
| 2021 | 4 | 125 | 3,469 | $621,024 | $65,635 |
| 2020 | 7 | 161 | 164 | $10,731 | $4,588 |
Total Patients
929
Total Services
54,530
Medicare Billing
$561,010
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 59 | 16,170 | $559,425 | $128,603 | 23.0% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 26 | 7,952 | $282,074 | $74,934 | 26.6% |
| J2356 | Injection, tezepelumab-ekko, 1 mg | Office | 2023 | 11 | 3,360 | $182,817 | $42,304 | 23.1% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 11 | 2,200 | $119,590 | $29,773 | 24.9% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 14 | 7,200 | $190,386 | $28,093 | 14.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 960 | $74,826 | $17,707 | 23.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 60 | 89 | $64,457 | $3,736 | 5.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 36 | 59 | $60,868 | $2,783 | 4.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 24 | 27 | $50,854 | $2,292 | 4.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 113 | 235 | $65,967 | $2,189 | 3.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 33 | $8,878 | $447.16 | 5.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 12 | 60 | $1,968 | $355.74 | 18.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 12 | 28 | $6,427 | $281.82 | 4.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 69 | 5,040 | $456,019 | $87,184 | 19.1% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2022 | 14 | 7,140 | $321,371 | $54,335 | 16.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 28 | 88 | $267,168 | $7,819 | 2.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 74 | 114 | $192,432 | $5,679 | 3.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 15 | 50 | $31,770 | $923.64 | 2.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 27 | 77 | $39,293 | $729.00 | 1.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 11 | 15 | $22,572 | $619.09 | 2.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 38 | 3,300 | $298,584 | $54,552 | 18.3% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 47 | 96 | $162,048 | $5,133 | 3.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 20 | 52 | $157,872 | $5,000 | 3.2% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 20 | 21 | $2,520 | $949.83 | 37.7% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Office | 2020 | 76 | 77 | $3,003 | $1,467 | 48.8% |
About Blanca Fernandez, NP-C
Blanca Fernandez, NP-C is a Family healthcare provider based in Oldsmar, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2016. The National Provider Identifier (NPI) number assigned to this provider is 1538512504.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Blanca Fernandez, NP-C has received a total of $309.96 in payments from pharmaceutical and medical device companies, with $31.94 received in 2023. These payments were reported across 17 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($309.96).
As a Medicare-enrolled provider, Fernandez has provided services to 929 Medicare beneficiaries, totaling 54,530 services with total Medicare billing of $561,010. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Oldsmar, FL
- Active Since 07/14/2016
- Last Updated 07/14/2016
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1538512504
Products in Payments
- TREMFYA (Drug) $77.79
- RINVOQ (Biological) $52.24
- EVENITY (Biological) $36.30
- Cimzia (Drug) $31.89
- FERAHEME (Drug) $23.92
- ACTHAR (Biological) $22.85
- SKYRIZI (Biological) $18.48
- ORENCIA (Biological) $18.33
- Arcalyst (Drug) $14.21
- Prolia (Biological) $13.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Oldsmar
Ms. Lisa Beachy, Aprn, APRN
Family — Payments: $15,192
Family $15,192
Elise Helmbrecht
Family — Payments: $3,706
Family $3,706
Mr. William Horvath, Aprn, APRN
Family — Payments: $1,671
Family $1,671
Edna Wilson, Aprn-C, APRN-C
Family — Payments: $1,582
Family $1,582
Mrs. Kimberly Clarke, Arnp, ARNP
Family — Payments: $1,096
Family $1,096
Mrs. Gina Vines, Aprn, APRN
Family — Payments: $964.57
Family $964.57